Clinical trial · Observational
Efficacy and Safety of Camrelizumab in Real-World Prospective Study
Efficacy and Safety of Camrelizumab for Chinese NSCLC Patients: a Prospective, Observational, Multicenter Real-World Study
NCT04793139CI-TRIAL-00050618unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- AE,Grade 3-5
- timeFrame
- From April 1, 2021 to Septeember 30, 2024
- description
- Safety of the general population:Serious Adverse Events (AE)，Grade 3-5.
Secondary outcomes (6)
- measure
- pCR
- timeFrame
- From April 1, 2021 to December 30, 2024
- description
- Neoadjuvant therapy population: pathological complete response rate (pCR).
- measure
- MPR
- timeFrame
- From April 1, 2021 to December 30, 2024
- description
- Neoadjuvant population: main pathological response rate (MPR)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Sign the informed consent and volunteer to participate in the study; 2. Non-small cell lung cancer confirmed by histological/cytopathological tests; 3. Age ≥18; 4. The investigators determined that patients should receive camrelizumab alone or in combination. Exclusion Criteria: 1. Patients who are also receiving other immunomedications or therapies; 2. Patients participating in other interventional studies; 3. Patients complicated with other malignant tumors; 4. Women who have been confirmed to be pregnant or lactating; 5. The Investigator considers the patient unsuitable for participation in any other condition of the study.
References
Publications (0)
Data not yet available
No reference posted for this study.